Androgenetic alopecia with male and female pattern hair loss. Androgenetic alopecia (male and female pattern hair loss)
Conditions
Interventions
Intervention 1: Intervention group: Group A will include patients who receive exosome therapy alone once a month for three months. Intervention 2: Intervention group: Group B will include patients who
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: "Man and woman aged 18 to 60 years, healthy and not pregnant" "Male pattern hair loss (MPHL) grade III to IV based on the Norwood-Hamilton scale" "Female pattern hair loss (FPHL) with early localized or diffuse hair loss corresponding to grade I-3 to III based on the Ludwig scale" Patients who are in a stable state of improvement or worsening after one year of treatment with medications such as minoxidil, finasteride, dutasteride, and spironolactone, or who continue to experience hair loss after six months of medication use. Patients who have undergone follicular unit extraction and transplantation and experience hair thinning and shedding in both the transplanted and non-transplanted areas of the scalp one year after surgery. Patients undergoing treatment and monitoring for estrogen, progesterone, testosterone, and other pituitary or thyroid replacement therapies, yet continue to experience hair thinning and shedding. Willingness and ability to provide written informed consent for photography and authorization prior to undergoing any study-related procedures.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blinded investigator global aesthetic improvement scale. Timepoint: Assessments will be conducted at baseline, monthly after each injection for a total of three months, and once more in the fourth month, which corresponds to one month after the final treatment session. Method of measurement: Ludwig and Hamilton scale questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient satisfaction. Timepoint: "At the end of four months from the start of the intervention". Method of measurement: Questionnaire.;Patient global aesthetic improvement scale. Timepoint: "At the end of four months from the start of the intervention". Method of measurement: Questionnaire.;Reported side effects. Timepoint: "At the end of four months from the start of the intervention". Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGhasem Rahmatpour Rokni, MD
Mazandaran University of Medical Sciences
Outcome results
None listed